The size of the medical tourism market in India is expected to touch US $8 billion by 2020 from its current worth of US $3 billion. This is due to the costs for healthcare in the developed countries is getting higher. For around 80% of the medical tourists cost is the major factor. Accredited facilities and cost-consciousness has made Singapore, Thailand, India, Malaysia, Taiwan, Mexico and Costa Rica.
Contact The Holiday Healer to learn more about the processes of Medical Tourism, Top Hospitals and Treatments.
Grant Thornton India’s National Managing Partner Vishesh Chandiok said “In these areas, India has the second largest number of accredited facilities after Thailand. The Indian Medical Tourism market is expected to grow from its current size of USD 3 billion to USD 7-8 billion by 2020”. In India, Kerala has the potential to increase their share to attract the medical tourists. Currently only 5 per cent of medical tourists are attracted by Kerala. Grant Thornton India Partner Vrinda Mathur said, Kerala is already attracting medical tourists but it has to upgrade their infrastructure. The most favoured destinations for the medical tourists in India are Chennai, Mumbai, Andhra Pradesh and National Capital Region (NCR).
Other News
Imports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
TGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More
